In this Annual Report on Form 10-K, unless otherwise indicated or the context otherwise requires, all references to we, our, us, Centessa, the Company, and our Company refer to Centessa Pharmaceuticals plc and its consolidated subsidiaries. Overview We are a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. We are developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001847903-26-000025 | EDGAR | 114K words |
| 2025-03-24 | 2024-12-31 | 0001847903-25-000051 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001847903-24-000054 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001847903-23-000063 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001847903-22-000022 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001847903-25-000156 | EDGAR | 74K words |
| 2025-08-12 | 2025-06-30 | 0001847903-25-000135 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001847903-25-000072 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001847903-24-000167 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001847903-24-000128 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001847903-24-000081 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001847903-23-000189 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001847903-23-000155 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001847903-23-000097 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001847903-22-000084 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001847903-22-000049 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001847903-22-000031 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-134656 | EDGAR | 75K words |
| 2026-02-13 | 0001193125-26-051424 | EDGAR | — |
| 2025-12-11 | 0001193125-25-315074 | EDGAR | — |
| 2025-11-24 | 0001193125-25-292015 | EDGAR | — |
| 2025-11-13 | 0001193125-25-278827 | EDGAR | — |
| 2025-11-05 | 0001847903-25-000154 | EDGAR | — |
| 2025-08-12 | 0001847903-25-000133 | EDGAR | — |
| 2025-06-20 | 0001847903-25-000093 | EDGAR | — |
| 2025-06-17 | 0001847903-25-000090 | EDGAR | — |
| 2025-05-29 | 0001847903-25-000081 | EDGAR | — |
103 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001847903 |
| Ticker | CNTA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | X0 |
| Website | https://www.centessa.com |
| Listed | 2021-05-28 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CNTA (~200 tokens, structured JSON with cryptographic provenance)